News coverage about Express Scripts (NASDAQ:ESRX) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Express Scripts earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.9633944404388 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Express Scripts launches innovative pilot program for performance-based retail pharmacy network (seekingalpha.com)
- Is Express Scripts Holding Company’s (NASDAQ:ESRX) Balance Sheet Strong Enough To Weather A Storm? (finance.yahoo.com)
- Head to Head Survey: Express Scripts (ESRX) and HealthWarehouse.com (HEWA) (americanbankingnews.com)
- Express Scripts to close Ohio site, lay off 456 (bizjournals.com)
- Express Scripts to close Columbus site, lay off 456 (bizjournals.com)
Several equities research analysts recently commented on the stock. Sanford C. Bernstein downgraded shares of Express Scripts from a “market perform” rating to an “underperform” rating and upped their price target for the company from $55.80 to $77.50 in a research report on Tuesday, January 30th. Raymond James Financial restated a “sell” rating on shares of Express Scripts in a research report on Friday, December 15th. BidaskClub downgraded shares of Express Scripts from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Jefferies Group set a $91.00 price target on shares of Express Scripts and gave the company a “buy” rating in a research report on Wednesday, February 28th. Finally, William Blair downgraded shares of Express Scripts from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 8th. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $81.97.
Express Scripts stock traded up $1.89 during trading hours on Thursday, hitting $71.61. The company had a trading volume of 3,750,118 shares, compared to its average volume of 5,232,093. The firm has a market cap of $39,206.10, a PE ratio of 10.09, a P/E/G ratio of 0.86 and a beta of 0.99. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.55 and a current ratio of 0.67. Express Scripts has a fifty-two week low of $55.80 and a fifty-two week high of $85.07.
Express Scripts (NASDAQ:ESRX) last released its quarterly earnings data on Tuesday, February 27th. The company reported $2.16 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.09 by $0.07. The firm had revenue of $25.38 billion for the quarter, compared to analyst estimates of $25.07 billion. Express Scripts had a net margin of 4.51% and a return on equity of 25.19%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.88 EPS. equities analysts anticipate that Express Scripts will post 9.33 EPS for the current fiscal year.
Express Scripts declared that its board has authorized a stock buyback plan on Monday, December 18th that authorizes the company to repurchase 45,000,000 outstanding shares. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its shares are undervalued.
In other news, VP Everett Neville sold 4,895 shares of the stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $75.26, for a total transaction of $368,397.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Christine Houston sold 19,889 shares of the stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $76.69, for a total transaction of $1,525,287.41. The disclosure for this sale can be found here. Corporate insiders own 0.79% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Express Scripts (ESRX) Earning Somewhat Favorable News Coverage, Study Shows” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://ledgergazette.com/2018/04/12/express-scripts-esrx-earning-somewhat-favorable-news-coverage-study-shows.html.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.